Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vericiguat (BAY1021189) is a potent and orally available guanylate cyclase stimulator.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 48.00 | |
2 mg | In stock | $ 71.00 | |
5 mg | In stock | $ 128.00 | |
10 mg | In stock | $ 178.00 | |
25 mg | In stock | $ 319.00 | |
50 mg | In stock | $ 538.00 | |
100 mg | In stock | $ 769.00 | |
500 mg | In stock | $ 1,580.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 122.00 |
Description | Vericiguat (BAY1021189) is a potent and orally available guanylate cyclase stimulator. |
In vitro | Vericiguat inhibits the U46619-induced contractions of porcine coronary artery rings concentration-dependently (IC50: 956 nM). Vericiguat inhibits phenylephrine-induced contractions of rabbit saphenous artery rings, rabbit aortic rings, and canine femoral vein rings concentration-dependently (IC50: 798, 692, and 3072 nM, respectively). Vericiguat (0.01 μM to 100 μM) stimulates recombinant sGC concentration-dependently, by 1.7-fold to 57.6-fold. When combined with the NO donor diethylamine/nitric oxide complex, Vericiguat and DEA/NO have a synergistic effect on the enzyme activity over a wide range of concentrations. At the highest concentrations of Vericiguat (100 μM) and DEA/NO (100 nM), the specific activity of sGC is 341.6-fold above baseline. Vericiguat stimulates the sGC reporter cell line concentration-dependently (EC50: 1005±145 nM) [1]. |
In vivo | Vericiguat causes a significant and dose-dependent increase in survival rates. Chronic oral treatment with Vericiguat (3 or 10 mg/kg, q.d.) results in a significant attenuation of blood pressure increase during the course of the study. Vericiguat (3 or 10 mg/kg) treatment leads to a significant reduction in kidney injury molecule Kim-1 and osteopontin expression which are used as biomarkers for renal injury and dysfunction. In the 3 and 10 mg/kg q.d. treatment groups, the rat survival rate is 70% and 90%, respectively, at the study end [1]. |
Synonyms | BAY1021189 |
Molecular Weight | 426.38 |
Formula | C19H16F2N8O2 |
CAS No. | 1350653-20-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 45 mg/mL (105.54 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vericiguat 1350653-20-1 GPCR/G Protein Guanylate cyclase Inhibitor inhibit BAY 1021189 BAY1021189 Guanylate Cyclase BAY-1021189 inhibitor